Literature DB >> 24973808

Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease.

Taku Hatano1, Manabu Funayama2, Shin-Ichiro Kubo3, Ignacio F Mata4, Yutaka Oji3, Akio Mori3, Cyrus P Zabetian4, Sarah M Waldherr4, Hiroyo Yoshino5, Genko Oyama3, Yasushi Shimo6, Ken-Ichi Fujimoto7, Hirokazu Oshima8, Yasuto Kunii8, Hirooki Yabe8, Yoshikuni Mizuno3, Nobutaka Hattori9.   

Abstract

Leucine-rich repeat kinase 2 (LRRK2) is a causative gene of autosomal dominant familial Parkinson's disease (PD). We screened for LRRK2 mutations in 3 frequently reported exons (31, 41, and 48) in our cohort of 871 Japanese patients with PD (430 with sporadic PD and 441 probands with familial PD). Direct sequencing analysis of LRRK2 revealed 1 proband (0.11%) with a p.R1441G mutation, identified for the first time in Asian countries, besides frequently reported substitutions including, the p.G2019S mutation (0.11%) and p.G2385R variant (11.37%). Several studies have suggested that the LRRK2 p.R1441G mutation, which is highly prevalent in the Basque country, is extremely rare outside of northern Spain. Further analysis of family members of the proband with the p.R1441G mutation revealed that her mother and first cousin shared the same mutation and parkinsonism. Haplotype analysis revealed a different haplotype from that of the original Spanish families. Our patients demonstrated levodopa-responsive parkinsonism with intrafamilial clinical heterogeneity. This is the first report of familial PD because of the LRRK2 p.R1441G mutation in Asia.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Asia; Intrafamilial clinical heterogeneity; LRRK2; Parkinson's disease; p.R1441G

Mesh:

Substances:

Year:  2014        PMID: 24973808      PMCID: PMC4171438          DOI: 10.1016/j.neurobiolaging.2014.05.025

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  30 in total

1.  Familial Parkinson's disease: clinical and genetic analysis of four Basque families.

Authors:  Coro Paisàn-Ruìz; Amets Sàenz; Adolfo Lòpez de Munain; Itxaso Martì; Angel Martìnez Gil; Josè F Martì-Massò; Jordi Pèrez-Tur
Journal:  Ann Neurol       Date:  2005-03       Impact factor: 10.422

2.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

Authors:  Laurie J Ozelius; Geetha Senthil; Rachel Saunders-Pullman; Erin Ohmann; Amanda Deligtisch; Michele Tagliati; Ann L Hunt; Christine Klein; Brian Henick; Susan M Hailpern; Richard B Lipton; Jeannie Soto-Valencia; Neil Risch; Susan B Bressman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

3.  Identification and haplotype analysis of LRRK2 G2019S in Japanese patients with Parkinson disease.

Authors:  C P Zabetian; H Morino; H Ujike; M Yamamoto; M Oda; H Maruyama; Y Izumi; R Kaji; A Griffith; B C Leis; J W Roberts; D Yearout; A Samii; H Kawakami
Journal:  Neurology       Date:  2006-05-25       Impact factor: 9.910

4.  Lrrk2 and Lewy body disease.

Authors:  Owen A Ross; Mathias Toft; Andrew J Whittle; Joseph L Johnson; Spiridon Papapetropoulos; Deborah C Mash; Irene Litvan; Mark F Gordon; Zbigniew K Wszolek; Matthew J Farrer; Dennis W Dickson
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

5.  Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes.

Authors:  Kazuko Hasegawa; A Jon Stoessl; Teruo Yokoyama; Hisayuki Kowa; Zbigniew K Wszolek; Saburo Yagishita
Journal:  Parkinsonism Relat Disord       Date:  2008-09-18       Impact factor: 4.891

6.  Genetic analysis of LRRK2 mutations in patients with Parkinson disease.

Authors:  Hao Deng; WeiDong Le; Yi Guo; Christine B Hunter; WenJie Xie; MaoSheng Huang; Joseph Jankovic
Journal:  J Neurol Sci       Date:  2006-11-09       Impact factor: 3.181

7.  Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism.

Authors:  Owen A Ross; Cleanthe Spanaki; Alida Griffith; Chin-Hsien Lin; Jennifer Kachergus; Kristoffer Haugarvoll; Helen Latsoudis; Andreas Plaitakis; Joaquim J Ferreira; Cristina Sampaio; Vincenzo Bonifati; Ruey-Meei Wu; Cyrus P Zabetian; Matthew J Farrer
Journal:  Parkinsonism Relat Disord       Date:  2008-10-26       Impact factor: 4.891

8.  Genetic neuropathology of Parkinson's disease.

Authors:  Mark R Cookson; John Hardy; Patrick A Lewis
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.

Authors:  K Haugarvoll; R Rademakers; J M Kachergus; K Nuytemans; O A Ross; J M Gibson; E-K Tan; C Gaig; E Tolosa; S Goldwurm; M Guidi; G Riboldazzi; L Brown; U Walter; R Benecke; D Berg; T Gasser; J Theuns; P Pals; P Cras; P Paul De Deyn; S Engelborghs; B Pickut; R J Uitti; T Foroud; W C Nichols; J Hagenah; C Klein; A Samii; C P Zabetian; V Bonifati; C Van Broeckhoven; M J Farrer; Z K Wszolek
Journal:  Neurology       Date:  2008-03-12       Impact factor: 9.910

10.  Autonomic dysfunction in parkinsonian LRRK2 mutation carriers.

Authors:  Beatriz Tijero; Juan Carlos Gómez Esteban; Johanne Somme; Verónica Llorens; Elena Lezcano; Ana Martinez; Trinidad Rodríguez; Koldo Berganzo; Juan José Zarranz
Journal:  Parkinsonism Relat Disord       Date:  2013-06-10       Impact factor: 4.891

View more
  7 in total

1.  Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.

Authors:  Guodong Huang; Daniel W Bloodgood; Jongkyun Kang; Anu Shahapal; Phoenix Chen; Konstantin Kaganovsky; Jae-Ick Kim; Jun B Ding; Jie Shen
Journal:  J Neurosci       Date:  2022-05-09       Impact factor: 6.709

2.  The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot.

Authors:  Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-04-25       Impact factor: 3.568

Review 3.  Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.

Authors:  Liesel Goveas; Eugénie Mutez; Marie-Christine Chartier-Harlin; Jean-Marc Taymans
Journal:  Cells       Date:  2021-04-22       Impact factor: 6.600

4.  Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Authors:  Mario Cornejo-Olivas; Luis Torres; Mario R Velit-Salazar; Miguel Inca-Martinez; Pilar Mazzetti; Carlos Cosentino; Federico Micheli; Claudia Perandones; Elena Dieguez; Victor Raggio; Vitor Tumas; Vanderci Borges; Henrique B Ferraz; Carlos R M Rieder; Artur Shumacher-Schuh; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Francisco Lopera; Jorge Chang-Castello; Brennie Andreé-Munoz; Sarah Waldherr; Dora Yearout; Cyrus P Zabetian; Ignacio F Mata
Journal:  NPJ Parkinsons Dis       Date:  2017-06-02

5.  Deep brain stimulation for monogenic Parkinson's disease: a systematic review.

Authors:  Tomi Kuusimäki; Jaana Korpela; Eero Pekkonen; Mika H Martikainen; Angelo Antonini; Valtteri Kaasinen
Journal:  J Neurol       Date:  2019-01-18       Impact factor: 4.849

Review 6.  Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort.

Authors:  Jan O Aasly
Journal:  Front Neurosci       Date:  2021-01-28       Impact factor: 4.677

Review 7.  Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.

Authors:  Paweł Turski; Iwona Chaberska; Piotr Szukało; Paulina Pyska; Łukasz Milanowski; Stanisław Szlufik; Monika Figura; Dorota Hoffman-Zacharska; Joanna Siuda; Dariusz Koziorowski
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.